ANI Pharmaceuticals Inc. has appointed Peter A. Lankau to its board of directors. Currently Lankau is on the board of advisors of Orchard Venture Partners and chair of the board at Phosphagenics Ltd. Prior to this, he was executive chair at Nautilus Neurosciences, Inc. and before this he was chair and CEO of Logical Therapeutics, Inc. Previously, he was CEO and director of Endo Pharmaceuticals Inc.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June-August 2014.

After fraud allegations involving its chief executive, Phosphagenics reports promising Phase I results for its transdermal oxymorphone patch.

It may have been only a small Phase I trial, but investors in Phosphagenics were sufficiently convinced by positive results with a new transdermal formulation of oxymorphone to send shares in the Australian drug delivery venture surging by nearly 50% on 24 October.